MetLife Investment Management’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.2M | Buy |
85,621
+8,063
| +10% | +$166K | 0.01% | 1099 |
|
|
2026
Q1 | $1.49M | Buy |
77,558
+2,394
| +3% | +$47.6K | 0.01% | 1213 |
|
|
2025
Q4 | $1.24M | Sell |
75,164
-3,911
| -5% | -$66K | 0.01% | 1306 |
|
|
2025
Q3 | $1.15M | Hold |
79,075
| – | – | 0.01% | 1362 |
|
|
2025
Q2 | $1.11M | Buy |
79,075
+4,310
| +6% | +$60.7K | 0.01% | 1252 |
|
|
2025
Q1 | $1.02M | Sell |
74,765
-1,285
| -2% | -$24.6K | 0.01% | 1355 |
|
|
2024
Q4 | $1.55M | Buy |
76,050
+4,240
| +6% | +$109K | 0.01% | 1188 |
|
|
2024
Q3 | $2.09M | Hold |
71,810
| – | – | 0.01% | 993 |
|
|
2024
Q2 | $1.67M | Buy |
71,810
+9,546
| +15% | +$183K | 0.01% | 1068 |
|
|
2024
Q1 | $1.28M | Hold |
62,264
| – | – | 0.01% | 1161 |
|
|
2023
Q4 | $1.34M | Hold |
62,264
| – | – | 0.01% | 1148 |
|
|
2023
Q3 | $1.28M | Hold |
62,264
| – | – | 0.01% | 1109 |
|
|
2023
Q2 | $1.84M | Buy |
62,264
+5,237
| +9% | +$147K | 0.01% | 967 |
|
|
2023
Q1 | $1.31M | Hold |
57,027
| – | – | 0.01% | 1086 |
|
|
2022
Q4 | $1.59M | Buy |
57,027
+4,600
| +9% | +$137K | 0.01% | 998 |
|
|
2022
Q3 | $1.61M | Buy |
52,427
+2,035
| +4% | +$66.2K | 0.01% | 974 |
|
|
2022
Q2 | $1.48M | Hold |
50,392
| – | – | 0.01% | 1022 |
|
|
2022
Q1 | $1.62M | Buy |
50,392
+18,003
| +56% | +$619K | 0.01% | 1079 |
|
|
2021
Q4 | $1.44M | Hold |
32,389
| – | – | 0.01% | 976 |
|
|
2021
Q3 | $1.63M | Hold |
32,389
| – | – | 0.01% | 935 |
|
|
2021
Q2 | $2.54M | Buy |
32,389
+7,625
| +31% | +$472K | 0.02% | 768 |
|
|
2021
Q1 | $1.41M | Hold |
24,764
| – | – | 0.01% | 985 |
|
|
2020
Q4 | $2.07M | Sell |
24,764
-3,348
| -12% | -$202K | 0.02% | 806 |
|
|
2020
Q3 | $1.01M | Hold |
28,112
| – | – | 0.01% | 1024 |
|
|
2020
Q2 | $680K | Buy |
28,112
+5,422
| +24% | +$127K | 0.01% | 1212 |
|
|
2020
Q1 | $397K | Buy |
22,690
+1,775
| +8% | +$37K | 0.01% | 1330 |
|
|
2019
Q4 | $364K | Hold |
20,915
| – | – | ﹤0.01% | 1630 |
|
|
2019
Q3 | $320K | Hold |
20,915
| – | – | ﹤0.01% | 1667 |
|
|
2019
Q2 | $434K | Sell |
20,915
-41,830
| -67% | -$937K | ﹤0.01% | 1569 |
|
|
2019
Q1 | $1.46M | Buy |
62,745
+41,830
| +200% | +$875K | ﹤0.01% | 1442 |
|
|
2018
Q4 | $432K | Hold |
20,915
| – | – | 0.01% | 1455 |
|
|
2018
Q3 | $455K | Buy |
+20,915
| New | +$346K | ﹤0.01% | 1594 |
|
|
2018
Q2 | – | Sell |
-12,469
| Closed | -$246K | – | 2183 |
|
|
2018
Q1 | $246K | Buy |
+12,469
| New | +$256K | ﹤0.01% | 1779 |
|
Other funds holding DNLI
MetLife Investment Management's DNLI Position: Q2 2026 in Review
MetLife Investment Management increased its Denali Therapeutics (DNLI) stake by 10% in Q2 2026, buying an estimated $166K and bringing the position to 85,621 shares worth $2.2M. The position accounts for 0.01% of the portfolio, ranked #1099.
MetLife Investment Management first reported a position in DNLI in Q1 2018 and has held it in 33 quarters since. The position peaked at $2.54M in Q2 2021. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- MetLife Investment Management held 85,621 shares of Denali Therapeutics worth $2.2M as of Q2 2026.
- MetLife Investment Management bought 8,063 Denali Therapeutics shares in Q2 2026, an estimated $166K.
- Denali Therapeutics made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1099 holding.
- MetLife Investment Management first reported a position in Denali Therapeutics in Q1 2018 and has held it in 33 quarters since.
- MetLife Investment Management's Denali Therapeutics position peaked at $2.54M in Q2 2021.
- 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.